Search
A lesser-known immune cell is suddenly getting more attention in the field of cancer immunology.
A class of drugs originally developed to treat certain neurological disorders appears to boost the production of red blood cells.
Researchers at MSK pioneered many discoveries in 2023. Read about some of the most important findings.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has joined the institution as President and Chief Executive Officer.
Learn about MSK’s visionary new cancer engineering PhD Program.
MSK researchers are learning more about how cancer cells can survive undetected for years only to return in new places. These insights will guide future therapies.
After 21 years of dedicated service, Elizabeth McCormick, MSN, RN, CENP, Senior Vice President, Chief Nursing Officer and Enid A. Haupt Chair, Department of Nursing, will retire from MSK at the end of 2021. During her tenure, Ms. McCormick transformed and ultimately redefined the role of nursing at MSK.
Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.
The effects of adoptive T cell therapy on mesothelioma and metastatic lung and breast cancers are the focus of a new Memorial Sloan Kettering Cancer Center trial, which, compared to some existing trials of therapy, offers some important differences for patients.